Sugi Predict

Sugi Predict / Compounds / SCHEMBL2619233

SCHEMBL2619233

SCHEMBL2619233

Cc1n[nH]c2cncnc12

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 2/20 0.39
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ PDPK1 O15530 1/20 0.35
▸ CYP1A2 P05177 1/20 0.32
▸ YTHDC1 Q96MU7 1/20 0.32
▸ YTHDF2 Q9Y5A9 1/20 0.32
▸ PIM1 P11309 1/20 0.31
▸ MAPK14 Q16539 1/20 0.30
▸ DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352379 0.75 GRM4 (0.39) GRM4MAPK14
SCHEMBL545813 0.75 GRM4 (0.39) GRM4MAPK14
SCHEMBL473498 0.75 GRM4 (0.39) GRM4MAPK14DYRK1A
SCHEMBL30132904 0.75 DYRK1A (0.52) GRM4PDPK1DYRK1A
SCHEMBL421235 0.75 DYRK1A (0.52) GRM4PDPK1DYRK1A
SCHEMBL473390 0.75 GRM4 (0.46) GRM4MAPK14
SCHEMBL11874314 0.75 GRM4 (0.39) GRM4MAPK14
SCHEMBL29414359 0.75 GRM4 (0.39) GRM4MAPK14
SCHEMBL15935281 0.75 GRM4 (0.37) GRM4
SCHEMBL2611031 0.75 GRM4 (0.37) GRM4MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
WO-2021254493-A1 CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF 上海翊石医药科技有限公司 2021-12-23 — — WO disclosed
EP-2935247-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2019-08-28 — — EP disclosed
EP-3498701-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2019-06-19 — — EP disclosed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 — — US disclosed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 — — US disclosed
EP-2935243-B1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF EPIZYME INC (US) 2018-03-14 — — EP disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 — — US disclosed
US-9765068-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-9745291-B2 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. (US) 2017-08-29 — — US disclosed
US-20090018335-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-15 — — US disclosed
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PLRAMED LIMITED (GB) 2008-02-14 — — US disclosed
US-20070244132-A1 Fused Heterocyclic Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-10-18 — — US disclosed
EP-1752457-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-02-14 — — EP disclosed
EP-1675858-A2 5-ARYL-PYRAZOLO [4,3-D] PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2006-07-05 — — EP disclosed
WO-2005028480-A2 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2005-03-31 — — WO disclosed
US-20050070542-A1 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds NEUROGEN CORPORATION 2005-03-31 — — US disclosed
EP-0824533-B1 PYRAZOLO-(1,5a)-PYRIMIDINES, PROCESS FOR PREPARING THE SAME AND THEIR USE BASF AG (DE) 2001-11-14 — — EP disclosed
US-5902773-A PESTICIDES AND FUNGICIDES FORMED BY MULTISTAGE REACTIONS, WITTIG REACTION WITH BENZALDEHYDE BASF AKTIENGESELLSCHAFT (DE) 1999-05-11 — — US disclosed
WO-1996035690-A1 PYRAZOLO-(1,5a)-PYRIMIDINES, PROCESS FOR PREPARING THE SAME AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1996-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244132-A1 Fused Heterocyclic Compound NOX3, ERBB3, CBR3 GRM4 1004/4885ADORA2A 2606/4885ADORA2B 2477/4885
US-20050070542-A1 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds CRHR1, HTR5A, HTR1D GRM4 163/4885ADORA2A 138/4885ADORA2B 115/4885
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PIK3CA, PI4KB, PI4KA GRM4 3176/4885ADORA2A 4258/4885ADORA2B 3915/4885
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES C1R, C9, C1S GRM4 4425/4885ADORA2A 1355/4885ADORA2B 351/4885
US-20090018335-A1 FUSED HETEROCYCLIC COMPOUND NOX3, ERBB3, CBR3 GRM4 1004/4885ADORA2A 2606/4885ADORA2B 2477/4885
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 GRM4 2189/4885ADORA2A 3882/4885ADORA2B 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.